The problem with big pharmas is that they have such a huge number of drugs that a drug that suddenly becomes a blockbuster (for instance, Brilacidin in some of its various applications) doesn't have the impact on the bottom line that it would have on a smaller company.

If we are going to speculate about buy-outs (which is NOT what the CEO says his aim for the company is*), then the ideal partner would be a smaller biotech, not one of the giants, and one that gives stock not cash so that it's not a taxable event. A smaller biotech could have a massive boost to its bottom line if it suddenly got a blockbuster drug or three.


* (the CEO has said he'd like to see IPIX be a royalty company -- continuing to develop drugs while cash flows in from partnerships)